Studies inflating antidepressant efficacy?

Yesterday we reported on an article published in the New England Journal of Medicine that found studies with positive results were far more likely to be published than those with negative results. The study found that the FDA is working with raw data, whereas medical journals are not, which can contribute to misleading results about the efficacy of certain drugs, particularly antidepressants. And the folks over at the blog Clinical Psychology and Psychiatry have an in-dept look at exactly which antidepressants may have inflated benefits due to data suppression. The list includes Wellbutrin, Celexa, Cymbalta, Lexapro, Prozac, Remeron, Serzone, Paxil, Zoloft, and Effexor--every antidepressant approved between 1987 and 2004.

- see this blog entry for more

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.